Closed · W81XWH-22-PRCRP-TTSA · CFDA 12.420 · Discretionary
DoD Peer Reviewed, Translational Team Science Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- August 2, 2022
- Close date
- 9
- Expected awards
The verdict
DoD Peer Reviewed, Translational Team Science Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 9 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 9
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoD Peer Reviewed, Translational Team Science Award - is cataloged under number W81XWH-22-PRCRP-TTSA and tied to CFDA assistance listing 12.420, posted by Defense Health Agency Contracting Activity - DHACA. Grants.gov currently shows the opportunity as closed, first posted on March 31, 2022 and last updated on April 25, 2022. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. The agency has projected $36.0 million in total estimated funding for this announcement. It expects to issue 9 awards. If the agency funds the expected 9 awards from the $36.0 million estimated pool, the average award works out to roughly $4.0 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on August 2, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
August 2, 2022
Posted
March 31, 2022
Est. Total Funding
$36,000,000
Expected Awards
9
Instrument
Grant
Description
The FY22 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies must be associated with ongoing or completed clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations and to utilize information from the clinical trials for research that would then inform the clinic. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings. The TTSA is not intended to support high-throughput screenings, sequencing. The goal of the TTSA is to bring together a synergistic team of investigators to address clinical problems that may have an impact on patient outcomes. Important aspects of the TTSA mechanism are as follows: · Collaboration: The TTSA offers a unique opportunity for multiple investigators to partner on one research project. The success of the project depends on the unique skills and contributions of each collaborator. At least two, and up to three, Principal Investigators (PIs) must partner in one overarching study in at least one of the required FY22 PRCRP Topic Areas. At least one military or VA investigator is strongly encouraged to be included as an equal partner in the research, offering both intellectual investment and research effort. A military or VA investigator is defined as an investigator who is active duty or active reserve and detailed to agencies outside of the DOD, civilian DOD investigators, or an investigator at a VA research facility. The military/VA investigator should have a substantial role in the research and should not be included only for access to active-duty military and/or VA populations. · Translation: The application should provide evidence for the reciprocal transfer of information between basic and clinical science or vice-versa in developing and implementing the research plan. Translational research should be based on clinical trials. The application · should demonstrate how the study will leverage clinical information to address knowledge gaps in resulting outcomes, validate key research findings, and expand upon potentially translational results, or investigate novel findings. · Preliminary Data Required: Clinical data that are relevant to the proposed studies must be included in the application and/or citations of the investigators’ work. · Data Evaluation: The proposed research should be rigorously designed to include a statistical plan and data analysis plan. The Translational Team Science Award is intended to have near-term relevance to patients; therefore, the statistical plan and data analysis plan should represent how significant the results and/or outcomes may be on patient outcomes. · Impact: The proposed research should have the potential to have a significant impact on cancer research and/or patient care and the potential to accelerate the movement of promising ideas (in prevention, detection, diagnosis, prognosis, treatment, and/or survivorship) into clinical applications in at least one of the FY22 PRCRP Overarching Challenges in Section II.A.3.
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |